TREM2‐Mediated Cholesterol Efflux in Macrophages Inhibits Anti‐Tumor Immunity via Limitation of CD4 + T and NK Cells
Open Access
- 20 October 2025
- journal article
- Published by Wiley in Advanced Science
- Vol. 13 (5) , e06995
Abstract
Tumor‐associated macrophages (TAMs) predominantly exert functions that facilitate tumor progression. Triggering receptor expressed on myeloid cell 2 (TREM2) is expressed in TAMs, playing a crucial role in mediating the immunosuppressive function of TAMs. The mechanisms by which TREM2 + TAMs promote tumor growth and inhibit anti‐tumor immunity remain unclear. Through single‐cell sequencing of tumor tissues derived from wild‐type and Trem2 knockout mice bearing subcutaneous lung cancer, it is found that TREM2 deletion hindered tumor growth, with a notable increase in and improved functionality of CD4 + T and natural killer (NK) cells in the tumor microenvironment. TREM2 deficiency led to ATP‐binding cassette transporter A1 (ABCA1) downregulation, causing cholesterol accumulation in TAMs and promoting a pro‐inflammatory phenotype. This results in increased chemokine (C‐X3‐C motif) ligand 1 (CX3CL1) secretion of macrophages, recruiting more CD4 + T and NK cells to the tumor site, enhancing the anti‐tumor response. After screening food and drug administration (FDA)‐approved drugs, bortezomib and ataluren are found to effectively inhibit TREM2 expression in TAMs, indicating a potential therapeutic strategy against TREM2. This study elucidates the mechanism by which TREM2 shapes the immunosuppressive microenvironment and promotes tumorigenesis, highlighting TREM2 as a target for cancer immunotherapy.Keywords
Funding Information
- National Natural Science Foundation of China (82350121)
- National Natural Science Foundation of China (82573155)
- National Natural Science Foundation of China (U24A20734)
- National Natural Science Foundation of China (82272873)
This publication has 65 references indexed in Scilit:
- Distinct roles of TREM2 in central nervous system cancers and peripheral cancersCancer Cell, 2024
- Platinum‐Based TREM2 Inhibitor Suppresses Tumors by Remodeling the Immunosuppressive MicroenvironmentAngewandte Chemie International Edition, 2022
- Crosstalk between IL‐15Rα + tumor‐associated macrophages and breast cancer cells reduces CD8 + T cell recruitmentCancer Communications, 2022
- Immunosuppressive TREM2(+) macrophages are associated with undesirable prognosis and responses to anti-PD-1 immunotherapy in non-small cell lung cancerCancer Immunology, Immunotherapy, 2022
- Tanshinone IIA enhances susceptibility of non-small cell lung cancer cells to NK cell-mediated lysis by up-regulating ULBP1 and DR5Journal of Leukocyte Biology, 2021
- Tumor purity as a prognosis and immunotherapy relevant feature in gastric cancerCancer Medicine, 2020
- High-Dimensional Analysis Delineates Myeloid and Lymphoid Compartment Remodeling during Successful Immune-Checkpoint Cancer TherapyCell, 2018
- Atorvastatin suppresses inflammatory response induced by oxLDL through inhibition of ERK phosphorylation, IκBα degradation, and COX‐2 expression in murine macrophagesJournal of Cellular Biochemistry, 2011
- Macrophage Diversity Enhances Tumor Progression and MetastasisCell, 2010
- Dendritic cells modified to express fractalkine/CX3CL1 in the treatment of preexisting tumorsEuropean Journal of Immunology, 2006